Adenosine A(2A) receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

BackgroundWe evaluated the efficacy and safety of istradefylline, a selective adenosine A(2A) receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson’s disease patients with motor complications in Japan. MethodsA total of 373 subjects w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Yoshikuni, Kondo, Tomoyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842830/
https://www.ncbi.nlm.nih.gov/pubmed/23483627
http://dx.doi.org/10.1002/mds.25418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842830/
https://www.ncbi.nlm.nih.gov/pubmed/23483627
http://dx.doi.org/10.1002/mds.25418

Ejemplares similares